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Abstract
Introduction: Morbidity, mortality and social cost of sepsis are high. Previous studies have suggested that individual
cytokines levels could be used as sepsis markers. Therefore, we assessed whether the multiplex technology could identify
useful cytokine profiles in Emergency Department (ED) patients.
Methods: ED patients were included in a single tertiary-care center prospective study. Eligible patients were .18 years and
met at least one of the following criteria: fever, suspected systemic infection, $2 systemic inflammatory response syndrome
(SIRS) criteria, hypotension or shock. Multiplex cytokine measurements were performed on serum samples collected at
inclusion. Associations between cytokine levels and sepsis were assessed using univariate and multivariate logistic
regressions, principal component analysis (PCA) and agglomerative hierarchical clustering (AHC).
Results: Among the 126 patients (71 men, 55 women; median age: 54 years [19–96 years]) included, 102 had SIRS (81%), 55
(44%) had severe sepsis and 10 (8%) had septic shock. Univariate analysis revealed weak associations between cytokine
levels and sepsis. Multivariate analysis revealed independent association between sIL-2R (p=0.01) and severe sepsis, as well
as between sIL-2R (p=0.04), IL-1b (p=0.046), IL-8 (p=0.02) and septic shock. However, neither PCA nor AHC distinguished
profiles characteristic of sepsis.
Conclusions: Previous non-multiparametric studies might have reached inappropriate conclusions. Indeed, well-defined
clinical conditions do not translate into particular cytokine profiles. Additional and larger trials are now required to validate
the limited interest of expensive multiplex cytokine profiling for staging septic patients.
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Introduction
Despite rapid improvement in health care over the past decades,
sepsis continues to be a major life-threatening condition in acute
care patients [1]. The rise of antibiotic resistance is also a major
challenge that calls for novel biomarkers to guide and limit
prescription. In the Emergency Department (ED) and intensive
care unit, sepsis can be particularly difficult to distinguish from
other non-infectious conditions in patients with clinical signs of
acute inflammation. This issue is of outstanding importance given
that treatments and outcomes greatly differ between patients with
and without sepsis [2]. To date, biomarkers that are able to
distinguish between systemic inflammatory response syndrome
(SIRS) and the various forms of sepsis, such as severe sepsis or
septic shock, are neither sensitive nor specific enough [3–5]. One
available strategy is to monitor changes in pro- and anti-
inflammatory molecules associated with the host response to
pathogens. Hence, circulating levels of procalcitonin, C-reactive
protein, interleukin (IL)-1, IL-6, IL-8, IL-10, tumor necrosis factor
alpha (TNF-a), Fas-ligand, and monocyte chemoattractant protein
1 (MCP-1) have all been highlighted as potential markers of sepsis
[6–16]. However, these biomarkers have mostly been studied
individually and not altogether in multiparameter studies, while
there is tremendous redundancy in their functions. Furthermore,
in such a complex network of interaction, one cytokine can
compensate for another and multiple cytokines may be involved
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hypothesized that comprehensive profiling of serum levels of
multiple cytokines would provide greater insight into their utility
for staging patients with sepsis, compared with previous studies
focusing on single biomarkers. Novel multiplex technologies,
which rely on a combination of fluorescent-dyed microspheres
associated with a two-laser flow cytometry based system, allow
reliable measurement of a broad panel of cytokines using small
volumes of serum [6,14,17]. In this study, we quantitatively
analyzed 22 cytokines, chemokines and growth factors in serum
samples obtained from a single-center cohort of 126 patients
attending the emergency department with acute onset diseases.
We have evaluated these cytokines both individually, but more
importantly, together as profiles, using various multiparameter
methods. The primary aim of this study was to identify cytokine
profiles that would be characteristic of the various forms of sepsis,
as well as the identification of potential novel therapeutic targets in
sepsis.
Methods
Study design and patient selection
Over a four-month period, 126 patients were included in a
prospective observational cohort study conducted in the Emer-
gency department of Pitie ´-Salpe ˆtrie `re hospital (Paris, France), an
urban, 1600-bed tertiary care center and teaching hospital with
60,000 emergency department visits per year. Eligible patients met
the following criteria: age over 18 years, and an acute onset
medical condition defined as at least one of the following criteria:
fever (defined by a tympanic temperature $38uC at the nurse
triage) and/or suspected systemic infection and/or two or more
SIRS criteria [18] and/or hypotension (defined as systolic blood
pressure of ,90 mmHg) and/or shock. We excluded patients with
trauma, pregnant and breast-feeding women, patients with
cardiopulmonary arrest that required basic cardiac life support
measures, and those who received intravenous fluid resuscitation,
antibiotics, catecholamines or intravenous corticosteroids before
enrolment. Informed consent and approval by our institutional
review board (Comite ´ de Protection des Personnes Pitie ´-Salpe ˆ-
trie `re, Paris, France) were obtained before onset of the study.
Data collection
Data collected at enrollment included patient characteristics,
comorbidities, vital signs, respiratory parameters, routine blood
tests, suspected source of infection, microbiological culture results,
patient’s severity according to the Mortality in Emergency
Department Sepsis score (MEDS) [19], treatments and final
diagnosis. Routine biological investigations, microbiological tests
and antimicrobial therapy were prescribed by ED physicians
according to our ED standard of care. Included patients were
classified as having SIRS, sepsis, severe sepsis, or septic shock at
the time of admission by two independent ED experts physicians
(V.L & G.J), according to the ACCP/SCCM criteria and
to the SCCM/ESICM/ACCP/ATS/SIS International Sepsis
Definitions Conference [18,20]. In case of disagreement, the final
classification was determined by a majority opinion after
additional review of the patient’s medical file with a third ED
expert’s physician (P.H). The same methodology was applied to
classify patients as having viral, bacterial or infection of unknown
origin (after reviewing the medical files and follow-up by the
experts) in case of a diagnosis of infection not microbiologically
documented. The percentage of agreement between these two
independent investigators was excellent (97%) and the inter-rater
reliability was high (k=0.93). Thirty-day mortality was recorded.
Sample preparation and cytokine measurement
Venous blood samples were collected in the emergency room at
study inclusion before any treatment (including fluid infusion) was
administered, into apyrogen Becton Dickinson VacutainerH tubes
containing clot activator (Franklin Lakes, NJ, USA) and processed
immediately. After centrifugation at 2000 g for 10 min, serum
samples were stored at 280uC and thawed only once. Clots of fibrin
were removed from defrosted samples by a second centrifugation at
12,000 g for 10 min, and these samples were immediately used for
the Multiplex cytokine analysis measurement using Invitrogen
LuminexH Human cytokine 25-plex antibody bead kit (Invitrogen,
Carlsbad, CA, USA), which contains beads for the following
cytokines: TNF-a, IL-1b, IL-1 receptor antagonist (IL-1RA), IL-2,
soluble IL-2 receptor (sIL-2R), IL-4, IL-5, IL-6, IL-7, IL-8, IL-10,
IL-12, IL-13, IL-15, IL-17, Chemokine ligand (CCL)11 or Eotaxin,
granulocyte-macrophage colony-stimulating factor (GM-CSF),
Interferon (IFN)-a, IFN-c, CCL2 or Monocyte chimoattractant
protein 1 (MCP-1), CCL3 or Macrophage inflammatory protein-1a
(MIP-1a), CCL4 (MIP-1b), CCL5 or Regulated upon Activation
Normal T-cell Expressed and Secreted (RANTES), chemokine (C-
X-C motif) ligand 9 (CXCL9) or Monokine induced by gamma-
Interferon (MIG), and CXCL10 or Interferon gamma-induced
protein 10 (IP-10). The cytokines included in this analysis were
chosen for several reasons: i) we used a widely available commercial
panel (Invitrogen 25-plex) so that replicate studies may be easily
performed; ii) This panel allows the simultaneous assessment of a
large panel of both cytokines and chemokines; iii) many of them
have already been involved in the pathogenesis of sepsis in previous
studies; iiii) this panel includes both pro- and anti-inflammatory
cytokines and thus allows assessment of a broad spectrum of
Table 1. Patients’ characteristics.
Variable
Whole cohort
(n=126)
Men/Women, n (%) 71 (56%)/
55(44%)
Age, median (range), years 54 (19–96)
Pulse rate, median (range), beats/min 105 (28–146)
Respiratory rate, median (range), breaths/min 27 (12–44)
SBP median (range), mmHg 126 (40–220)
Temperature, median (range), 6C 38.2 (33.5–40.4)
SpO2, median (range), % 97 (80–100)
GSC, median (range) 15 (3–15)
Creatinin, median (range), mmol/L 71 (33–843)
WBC, median (range), G/L 10.2 (0.2–39.1)
Platelets, median (range), G/L 218 (17–805)
Total bilirubin median (range), mmol/L 12 (4–86)
pH, median (range) 7.43 (7.14–7.64)
CRP, median (range), mg/L 86 (3–410)
Procalcitonin, median (range), mg/L 0.54 (0.02–589)
Lactate level, median (range), mmol/L 1.8 (0.5–11.9)
MEDS score, median (range) 3 (0–19)
Hospitalization, n (%) 102 (80.9%)
Deaths, n (%) 12 (9.5%)
SBP: systolic blood pressure. SpO2: peripheral pulse oxymetry, GCS: Glasgow
coma scale, WBC: white blood cell, CRP; C Reactive Protein, MEDS: Mortality in
Emergency Department Sepsis.
doi:10.1371/journal.pone.0028870.t001
Cytokine Profiles and Sepsis
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28870immune responses.. All samples were masked for subject identity
and analyzed according to the manufacturer’s instructions, using a
sample dilution of 1:4. Duplicate wells containing negative controls
were used to estimate background intensity. Duplicate measure-
ments of a 7-step, 3-fold dilution series of known standards were
used to fit a 5-parameters logistic curve. One patient was excluded
from analysis because cytokine measurement failed for more than
33% of the 25 cytokines studied. IL-7, IP-10 and RANTES were
excluded from the subsequent analyses due to inadequate bead
counts or unreliable performance of standard curves. Samples with
non-detectable values were replaced by zero for the purpose of
continuous data analyses. All measurements were performed
blinded to the clinical history.
Statistical analysis
Quantitative data were expressed as median (minimum-
maximum) values and qualitative data as numbers and percent-
ages. The non-parametric Mann-Whitney test was used for
comparison of continuous variables between the various groups
of interest. Fischer’s exact test or the Khi-2 test was used for
comparing categorical variables. All analyses performed during
this study have been performed according to a 3-step process.
First, associations between individual cytokine levels and the
following outcomes of interest: SIRS, sepsis, severe sepsis, septic
shock, bacterial infection and bacterial infection in febrile patients
were assessed in univariate analyses using the non-parametric
Mann-Whitney test. Because performing several such comparisons
strongly increases the statistical risk of type I error (i.e, the risk to
observe false positive results), these analyses were followed by
Bonferroni correction for multiple testing, when needed. Corre-
lations between cytokine levels and severity scores were assessed
using Spearman’s non-parametric correlation test. Second, we
built multivariate logistic regression and multiple linear regression
models to identify cytokines independently associated with
outcomes of interest and severity scores, respectively. This is a
very important step to determine whether a given association
observed in univariate analysis remains independent when other
cytokines are taken into account. In these models, either the
outcomes of interest or the severity scores were used as dependent
variables, and all cytokines with p-values,0.20 in univariate
analyses were included as explanatory variables. Third, multidi-
mensional analyses were performed to assess whether the various
conditions of interest may be distinguished based on multiple
cytokine profiles. Principal component analyses (PCA) were used
to visually assess whether patients with and without these
outcomes of interest could be distinguished using the cytokines
identified in both univariate and multivariate analyses. In PCA,
each patient is represented by a single point in a 3-dimensional
space in such a manner that the closer 2 patients are, the more
they share similar characteristics. The main idea of these analyses
is thus to assess whether patients with and without a given
outcome of interest may be regrouped within two different groups
or, on the contrary, cannot be distinguished. We also used
Table 2. Serum concentrations of cytokines in patients with and without SIRS.
Cytokine concentration values* P-values
Cytokines With SIRS (n=102) Without SIRS (n=24) Univariate
{ Multivariate
1
TNF-a 19.0 (12.5–109.6) 18.7 (11.8–24.4) 0.45 -
IL-1b 0.0 (0.0–244.3) 0.0 (0.0–133.8) 0.39 -
IL-1RA 670.7 (201.1–50,700) 513.9 (263.7–14,475) 0.17 0.37
IL-2 0.0 (0.0–108.5) 0.0 (0.0–85.0) 0.89 -
sIL-2R 828.5 (496.8–3,089) 958.1 (577.0–4,703) 0.41 -
IL-4 144.8 (93.2–202.7) 143.0 (78.9–213.3) 0.84 -
IL-5 0.0 (0.0–255.4) 0.0 (0.0–0.0) 0.49 -
IL-6 61.4 (0.0–11,490) 26.6 (0.0–1,637) 0.02 0.29
IL-8 43.4 (0.0–4,850) 19.0 (0.0–3,599) 0.09 0.59
IL-10 0.0 (0.0–238.9) 0.0 (0.0–302.4) 0.70 -
IL-12 853.0 (378.6–1,431) 834.5 (534.2–1,190) 0.12 0.40
IL-13 0.0 (0.0–356.7) 0.0 (0.0–0.0) 0.09 0.91
IL-15 0.0 (0.0–468.3) 0.0 (0.0–249.4) 0.53 -
IL-17 121.8 (93.3–128.2) 125.4 (95.5–177.5) 0.29 -
IFN-a 43.7 (31.3–155.4) 43.3 (29.0–700.0) 0.60 -
IFN-c 74.0 (48.6–132.9) 72.8 (49.4–88.8) 0.65 -
MCP-1 454.2 (97.4–22,000) 311.0 (154.8–3,023) 0.14 0.93
MIG 60.1 (19.0–6,900) 63.7 (37.6–1,652) 0.92 -
MIP-1a 56.0 (44.7–1,749) 56.0 (49.4–680.5) 0.83 -
MIP-1b 83.1 (33.0–3,531) 72.9 (44.8–449.8) 0.26 -
Eotaxin 62.2 (21.7–462.2) 59.3 (16.8–222.6) 0.35 -
GM-CSF 0.0 (0.0–569.9) 0.0 (0.0–71.8) 0.29 -
*Expressed in median (min-max); unit is pg/ml. Samples with non-detectable cytokine levels were considered to be zero pg/ml.
{Assessed using the Mann-Whitney test.
1Assessed using multiple logistic regression (all p-values,0.20 in univariate analyses were entered in the multivariate model).
doi:10.1371/journal.pone.0028870.t002
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delineation of subgroups of patients sharing similar characteristics
within a population of interest, to assess whether patients with
and without the outcomes of interest could be distinguished using
the cytokines identified in both univariate and multivariate
analyses. During these analyses, patients with similar character-
istics are regrouped within clusters. The main idea is to check
whether patients with and without a given outcome of interest are
clustered within two different groups or, on the contrary, cannot
be distinguished. The primary method used for agglomerating
clusters was Ward’s method [21]. This was performed after
standardization of cytokine levels, so that each cytokine would
contribute in similar manner to the final classification. Since
other methods for linking clusters (single linkage, complete
linkage, group average) exist, we also used these latter, and
obtained similar results (data not shown). All p-values were two-
tailed and statistical significance was defined as p,0.05.
Statistical analyses were performed using JMP8 (SAS institute,
Cary, NC) and GraphPad Prism v5.0 (GraphPad Software, San
Diego, CA).
Results
Patients characteristics
We included 126 consecutive patients (71 men and 55 women)
with a median age of 54 years (range: 19–96 years) (table 1).
Among them, 99 patients had an acute infection (viral: 19,
malaria: 2, tuberculosis: 3, bacterial infection: 75) and the
remaining 27 patients had miscellaneous acute medical conditions
(including 2 systemic vasculitis, 3 febrile neutropenia, 3 acute
anaphylaxis). Documented bacterial infections were gram-negative
bacilli (n=19), gram-positive cocci (n=12), and mycobacteria
(n=3). Primary sites of infection were pulmonary (n=54), urinary
tract (n=16), digestive tract (n=11), meningeal (n=4), cutaneous
(n=3), ear-nose-throat system (n=2), and could not be deter-
mined in 9 patients. Viral infections comprised 17 patients with
respiratory tract infections along with flu-like symptoms and
negative bacterial biomarkers (no viral cultures were performed), 1
patient with documented varicella-zoster infection, and 1 patient
with acute viral hepatitis. One hundred and two patients had SIRS
(81%), 89 (71%) had fever, 55 (44%) had severe sepsis and 10 (8%)
Figure 1. Principal component analysis and clustering of cytokine profiles in patients with (n=102) and without (n=24) SIRS.
Patients with (red dots) and without (blue dots) SIRS are represented according to the first three components computed using principal component
analysis of either all 22 cytokines (panel A), or a more limited profile using only IL1-RA, IL-6, IL-8, IL-12, IL-13 and MCP-1 (panel B). Hierarchical cluster
analysis using all 22 cytokines measured (panel C) and the limited profile (panel D) are also presented. The dendrogram at the bottom of panels C & D
shows the clustering of patients with (red lines) and without (blues lines) SIRS, according to the cytokine profile selected (dendrodram at the left). The
color map at the center indicates the cytokine levels for each patient (brightest green is lowest level and brightest red is higher level measured).
Altogether, these analyses show that SIRS patients cannot be distinguished from non-SIRS patients.
doi:10.1371/journal.pone.0028870.g001
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intensive care unit. Twelve patients (9%) were deceased at 30-days
follow-up. All patients with septic shock fulfilled the definition for
severe sepsis, and all these latter fulfilled the definition for SIRS.
Cytokine profiles in SIRS
Only IL-6 serum levels were significantly increased (p=0.02) in
patients with SIRS (table 2), but this result did not reach statistical
significance after Bonferroni’s correction for multiple testing.
Multiparameter analysis using multivariate logistic regression
model revealed that no cytokine of interest was independently
associated with SIRS (table 2). Both principal component analysis
and hierarchical clustering analyses underlined that SIRS patients
could not be segregated from the others (figure 1).
Cytokine profiles in severe sepsis
Serum sIL-2R was significantly decreased (p=0.04) in patients
with severe sepsis (table 3), but this result did not reach statistical
significance after Bonferroni’s correction. A multivariate logistic
regression model revealed that sIL-2R was independently
associated with severe sepsis (table 3). However, both principal
component analysis and hierarchical clustering revealed that
patients with severe sepsis could not be distinguished from those
without severe sepsis (figure 2).
Cytokine profiles in septic shock
IL-1b serum levels were significantly raised (p=0.04), while
IFNc (p=0.02) and sIL-2R (p=0.04) were significantly decreased
in patients with septic shock (table 4). However, these results did
not reach statistical significance after Bonferroni’s correction.
Multivariate logistic regression revealed that IL-1b (p=0.04), sIL-
2R (p=0.04) and IL-8 (p=0.02) were independently associated
with septic shock (table 4). However, both principal component
analyses and hierarchical clustering analysis could not distinguish
patients with septic shock from those without (figure 3).
Cytokine profiles in febrile patients with bacterial
infection
IL-8 was significantly raised (p=0.02) and IL-17 (p=0.01) and
GM-CSF (p=0.03) were significantly decreased in sera of febrile
patients with bacterial infection compared to those without
bacterial infection (table 5), but these results did not reach
statistical significance after Bonferroni’s correction. A multivariate
logistic regression model revealed that decreased serum levels of
IL-17 were independently associated with bacterial infection in
febrile patients (table 5). However, both principal component
analysis and hierarchical clustering analysis further demonstrated
that febrile patients with bacterial infection could not be
distinguished from those without bacterial infection (figure 4).
Table 3. Serum concentrations of cytokines in patients with and without severe sepsis.
Cytokine concentration values* P-values
Cytokines With severe sepsis (n=55) Without severe sepsis (n=71) Univariate
{ Multivariate
1
TNF-a 19.0 (14.3–109.6) 19.0 (11.8–56.3) 0.96 -
IL-1b 0.0 (0.0–244.3) 0.0 (0.0–220.0) 0.21 -
IL-1RA 749.6 (201.1–50,700) 629.1 (236.8–50,700) 0.22 -
IL-2 0.0 (0.0–108.5) 0.0 (0.0–90.2) 0.10 0.27
sIL-2R 814.7 (545.7–1,511) 866.9 (496.8–4,704) 0.04 0.01
IL-4 145.0 (115.7–174.3) 143.7 (78.9–213.3) 0.47 -
IL-5 0.0 (0.0–74.2) 0.0 (0.0–255.4) 0.85 -
IL-6 70.0 (0.0–11,490) 44.7 (0.0–11,490) 0.07 0.51
IL-8 43.5 (0.0–4,850) 31.4 (0.0–3,803) 0.20 0.94
IL-10 0.0 (0.0–238.9) 0.0 (0.0–302.4) 0.44 -
IL-12 847.4 (660.9–1,431) 851.9 (378.6–1,189) 0.95 -
IL-13 0.0 (0.0–96.4) 0.0 (0.0–356.7) 0.09 0.69
IL-15 26.5 (0.0–267.6) 27.0 (0.0–468.3) 0.75 -
IL-17 120.8 (97.7–145.3) 122.8 (93.3–177.5) 0.23 -
IFN-a 44.7 (38.0–72.3) 43.7 (29.0–699.5) 0.21 -
IFN-c 73.6 (55.9–132.9) 73.6 (48.6–119.6) 0.80 -
MCP-1 461.0 (113.6–22,000) 383.8 (97.4–22,000) 0.42 -
MIG 55.8 (38.3–6,900) 63.0 (19.0–1,652) 0.25 -
MIP-1a 55.6 (45.9–1,749) 56.7 (44.7–680.5) 0.10 0.81
MIP-1b 83.5 (47.2–3,531) 80.9 (33.0–855.0) 0.80 -
Eotaxin 63.4 (26.1–323.5) 59.5 (16.8–422.2) 0.51 -
GM-CSF 0 (0.0–569.9) 0 (0.0–333.7) 0.86 -
*Expressed in median (min-max); unit is pg/ml. Samples with non-detectable cytokine levels were considered to be zero pg/ml.
{Assessed using the Mann-Whitney test.
1Assessed using multiple logistic regression (all p-values,0.20 in univariate analyses were entered in the multivariate model).
doi:10.1371/journal.pone.0028870.t003
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sepsis. Patients with (red dots) and without (blue dots) severe sepsis are represented according to the first three components computed using
principal component analysis of either all 22 cytokines (panel A), or of a limited profile using only IL-13, IL-2, sIL-2R, IL-6, IL-8, MIP-1a (panel B).
Hierarchical cluster analysis using all 22 cytokines measured (panel C) and the more limited profile (panel D) are also presented. The dendrogram at
the bottom of panels C & D shows the clustering of patients with (red lines) and without (blues lines) severe sepsis, according to the cytokine profile
selected (dendrodram at the left). The color map at the center indicates the cytokine levels for each patient (brightest green is lowest level and
brightest red is highest level measured). Altogether, these analyses show patients with severe sepsis cannot be distinguished from those without.
doi:10.1371/journal.pone.0028870.g002
Table 4. Serum concentrations of cytokines in patients with and without septic shock.
Cytokine concentration values* P-values
Cytokines With septic shock (n=10) Without septic shock (n=116) Univariate
{ Multivariate
1
TNF-a 18.0 (16.7–109.7) 19.0 (11.8–56.3) 0.19 0.93
IL-1b 23.5 (0.0–244.3) 0.0 (0.0–234.9) 0.04 0.046
IL-1RA 1,200 (236.8–50,700) 633.7 (201.0–50,700) 0.58 -
IL-2 0.0 (0.0–102.5) 0.0 (0.0–108.5) 0.53 -
sIL-2R 755.2 (545.6–1,511) 844.9 (496.8–4,703) 0.04 0.04
IL-4 142.8 (122.2–156.8) 144.6 (78.9–213.3) 0.41 -
IL-5 0.0 (0.0–0.0) 0.0 (0.0–255.4) 0.70 -
IL-6 126.3 (0.0–910.7) 50.8 (0.0–11,490) 0.28 -
IL-8 197.9 (0.0–4,850) 37.7 (0.0–3,803) 0.17 0.02
IL-10 0.0 (0.0–238.9) 0.0 (0.0–302.4) 0.58 -
IL-12 774.6 (660.9–1,431) 851.4 (378.6–1,190) 0.11 0.15
IL-13 0.0 (0.0–0.0) 0.0 (0.0–356.7) 0.31 -
IL-15 28.0 (0.0–55.8) 26.5 (0.0–468.3) 0.95 -
IL-17 118.8 (102.0–142.5) 122.8 (93.3–177.5) 0.19 0.79
IFN-a 45.0 (39.5–59.2) 43.7 (29.0–699.5) 0.97 -
IFN-c 67.2 (60.0–78.4) 75.2 (48.6–132.9) 0.02 0.16
MCP-1 523.9 (117.9–1,723) 399.1 (97.4–22,000) 0.53 -
MIG 50.7 (38.3–2,952) 60.1 (19.0–6,900) 0.42 -
MIP-1a 56.8 (51.7–1,749) 55.8 (44.7–680.5) 0.26 -
MIP-1b 67.5 (51.3–3,531) 82.0 (33.0–855.0) 0.82 -
Eotaxin 68.6 (35.4–172.9) 61.6 (16.8–422.2) 0.85 -
GM-CSF 0.0 (0.0–57.0) 0.0 (0.0–569.9) 0.31 -
*Expressed in median (min-max); unit is pg/ml. Samples with non-detectable cytokine levels were considered to be zero pg/ml.
{Assessed using the Mann-Whitney test.
1Assessed using multiple logistic regression (all p-values,0.20 in univariate analyses were entered in the multivariate model).
doi:10.1371/journal.pone.0028870.t004
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IL-6 (p=0.01) and IL-8 (p=0.02) were significantly raised while
IL-17 (p=0.03) was significantly decreased in sera of patients with
bacterial infection compared to those without bacterial infection
(table 6), but these results did not reach statistical significance after
Bonferroni’s correction. A multivariate logistic regression model
revealed that decreased serum levels of IL-17 were independently
associated with bacterial infection (table 6). However, both
principal component analysis and hierarchical clustering analysis
further demonstrated that febrile patients with bacterial infection
could not be distinguished from those without bacterial infection
(figure 5). We repeated this analysis considering only the 31
patients with proven bacterial infection: IL-6 (p=0.03), IL-8
(p=0.02) were significantly raised in these patients compared
to those without bacterial infection, while IL-17 (p=0.02) was
significantly decreased in the former (table 7). Importantly, none of
these parameters remained significant after Bonferroni correction
or in the multivariate analyses, and neither principal component
analysis nor hierarchical clustering analysis were able to
distinguish between these two groups of patients based on their
cytokine profiles (figure 6).
Cytokine profiles and severity/mortality data
The prognostic value of serum cytokine levels was further
assessed by correlating severity scores with individual cytokine
levels and by studying associations between cytokine levels and
mortality. Only IL-6 serum levels correlated significantly, albeit
poorly, with the MEDS score (r=0.27, p=0.002). However,
multivariate analysis revealed that none of the cytokines analyzed
in this study was independently associated with the MEDS score.
Twelve patients (9%) died during the 30-days follow-up. IL-1b
(p=0.03) and IL-12 (p=0.03) serum levels were significantly
increased in patients who died as compared to those who survived.
However, multivariate analysis revealed that no cytokine was
Figure 3. Principal component analysis and clustering of cytokine profiles in patients with (n=10) and without (n=116) septic
shock. Patients with (red dots) and without (blue dots) septic shock are represented according to the first three components computed using
principal component analysis of either all 22 cytokines (panel A), or using only IFNc, sIL-2R, IL-1b, IL-12, IL-17, IL-8 and TNFa (panel B). Hierarchical
cluster analysis using all 22 cytokines measured (panel C) and more limited profiles only based on IFNc, sIL-2R, IL-1b, IL-12, IL-17, IL-8 and TNFa (panel
D) or sIL-2R, IL-1b, and IL-8 (panel E) are also presented. The dendrogram at the bottom of panels C, D & E shows the clustering of patients with (red
lines) and without (blues lines) septic shock, according to the cytokine profile selected (dendrodram at the left). The color map at the center indicates
the cytokine levels for each patient (brightest green is lowest level and brightest red is highest level measured). Altogether, these analyses show
patients with septic shock cannot be distinguished from those without.
doi:10.1371/journal.pone.0028870.g003
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that neither principal component analysis nor hierarchical
clustering analysis could distinguish patients who survived from
those who died (data not shown).
Discussion
In this study, we have quantitatively analyzed 22 cytokines,
chemokines and growth factors in serum samples obtained from a
single-center cohort of 126 consecutive patients with acute onset
diseases attending the ED of a single tertiary-care center. Unlike
most studies reported in the literature, we have assessed cytokine
levels not only individually, but also together as profiles using
various multiparameter approaches, including multiple logistic
regression, principal component analysis and hierarchical cluster-
ing. Our main finding is that previous associations commonly
reported between sepsis and individual cytokine levels are not
confirmed using these multiparameter techniques. Thus, we report
that there are no typical cytokine profiles associated with SIRS,
severe sepsis, septic shock and bacterial infection among febrile
patients.
Previous studies only using univariate analyses have suggested
that levels of IL-1, IL-6, IL-8, IL-10, TNF-a and MCP-1 could be
raised in septic patients [4,5,8,11,22–25]. However, these previous
studies are likely biased because: 1) univariate analyses are neither
able to account for the tremendous redundancy in cytokine
functions nor for the complex network of interaction that exists
between them; 2) they assessed only one or two selected cytokines
and thus did not take into account the higher number of pro- and
anti-inflammatory cytokines that may be involved in the host
response to pathogens; 3) multiple cytokine measurement with
ELISA techniques is a significant source of inter-assay variability.
In the present study, we have used the recent multiplex
technology which enabled us to simultaneously measure several
different cytokines. This ensured that cytokine level assessment was
performed homogenously. To avoid any a priori, we did not limit
our analysis to previously reported pro- and anti-inflammatory
markers of sepsis, as a wide panel of cytokines, chemokines and
growth factors was assessed. These analyses revealed variations in
serum cytokine levels between patients with and without SIRS,
severe sepsis, septic shock and febrile patients with bacterial
infection, but none of these results were significant when applying
the very stringent Bonferroni’s correction for multiple testing. This
is an important issue, as this correction does not appear to have
been used in previous studies [4,5,8,11,22–25].
As emphasized above, univariate analyses cannot take into
account the high level of interactions taking place between the 22
cytokines studied. This limitation was overcome in the present
study by further using various multiparameter analyses. We first
built multivariate logistic regression models. These analyses
revealed that elevated sIL-2R serum levels were independently
associated with severe sepsis and, furthermore that sIL-2R but also
Table 5. Serum concentrations of cytokines in febrile patients with and without bacterial infection.
Cytokine concentration values* P-values
Cytokines
Febrile patients with bacterial infection
(n=59)
Febrile patients without bacterial
infection (n=30) Univariate
{ Multivariate
1
TNF-a 18.8 (13.2–109.7) 19.2 (12.5–25.6) 0.19 0.08
IL-1b 0.0 (0.0–244.3) 0.0 (0.0–220.0) 0.55 -
IL-1RA 666.1 (236.8–50,700) 624.4 (201.1–22,333) 0.37 -
IL-2 0.0 (0.0–102.5) 0.0 (0.0–90.2) 0.77 -
sIL-2R 817.5 (545.7–3,069) 858.7 (496.8–4,703) 0.14 0.66
IL-4 142.8 (96.0–173.8) 146.8 (93.2–213.3) 0.06 0.60
IL-5 0.0 (0.0–0.0) 0.0 (0.0–255.4) 0.16 0.99
IL-6 85.3 (0.0–11,490) 42.8 (0.0–2,222) 0.06 0.88
IL-8 47.2 (0.0–4,850) 23.1 (0.0–570.8) 0.02 0.23
IL-10 0.0 (0.0–238.9) 0.0 (0.0–147.8) 0.31 -
IL-12 850.9 (582.4–1,431) 862.7 (378.6–1,190) 0.55 -
IL-13 0.0 (0.0–43.1) 0.0 (0.0–356.7) 0.07 0.60
IL-15 27.0 (0.0–108.3) 29.0 (0.0–458.3) 0.27 -
IL-17 119.8 (93.3–142.5) 124.8 (97.7–177.5) 0.01 0.01
IFN-a 44.0 (33.3–131.7) 43.7 (38.0–155.4) 0.82 -
IFN-c 72.0 (48.6–132.9) 76.0 (54.3–93.6) 0.33 -
MCP-1 422.5 (113.6–22,000) 395.0 (97.4–7,614) 0.55 -
MIG 52.9 (37.6–6,900) 61.6 (19.0–765.5) 0.59 -
MIP-1a 55.6 (47.1–1,749) 55.3 (44.7–642.4) 0.90 -
MIP-1b 84.1 (47.2–3,531) 77.5 (33.0–855.0) 0.60 -
Eotaxin 60.3 (28.4–422.2) 62.4 (21.7–216.8) 0.45 -
GM-CSF 0.0 (0.0–264.0) 0.0 (0.0–333.7) 0.03 0.17
*Expressed in median (min-max); unit is pg/ml. Samples with non-detectable cytokine levels were considered to be zero pg/ml.
{Assessed using the Mann-Whitney test.
1Assessed using multiple logistic regression (all p-values,0.20 in univariate analyses were entered in the multivariate model).
doi:10.1371/journal.pone.0028870.t005
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Thus, IL-1b and IL-8 may be independent predictors of
progression from severe sepsis to septic shock. This is further
supported by two small cohort studies, consisting of 50 and 30
patients respectively, suggesting a correlation between IL-8 levels
and mortality [8,17]. We also found that IL-17 was independently
associated with bacterial infection as well as with bacterial
infection among febrile patients but that none of the other
cytokines tested here was independently associated with SIRS.
Second, we performed principal component analysis which allows
processing of highly multidimensional data, using all 22 cytokine
parameters studied, in addition to an analysis of more focused
profiles using only cytokines of interest, as defined in univariate
and multivariate analyses. These principal component analyses
revealed that distinct cytokine profiles could not be attributed to
patients with SIRS, severe sepsis, septic shock, bacterial infection
or bacterial infection and fever. Third, we performed hierarchical
cluster analyses, the results of which confirmed that patients with
the various clinical outcomes included could not be regrouped and
distinguished from one another on the basis of the cytokine
parameters applied in this study.
While most studies reported previously were performed in
intensive care units where the patients already received massive
fluid resuscitation, catecholamines and/or antibiotics [5,6,8,17,
23,25,26], the major strength of the present study is that the
patient’s blood samples were taken in the emergency room before
they received any targeted treatment. However, we cannot formally
exclude that some of the usual treatments of patients, such as statins,
may have interfered with cytokine measurement or with host
responses to pathogens. Because the aim of this study was to stratify
routine patients in the Emergency Department, excluding those
receiving usual treatments would have likely biased this pragmatic
study. Importantly, not all patients had microbiologically docu-
mented infection, but this corresponds to the real life. It could be
argued that one of thelimitations of this study isthe moderate cohort
size,thesmallnumberofpatientswithsepticshock(n=10),aswellas
Figure 4. Principal component analysis and clustering of cytokine profiles in febrile patients with (n=59) and without (n=30)
bacterial infection. Febrile patients with (red dots) and without (blue dots) bacterial infection are represented according to the first three
components computed using principal component analysis of either all 22 cytokines (panel A), or a more limited profile using only GM-CSF, IL-13, IL-
4, IL-5, IL-6, sIL-2R, IL-17, IL-8 and TNF-a (panel B). Hierarchical cluster analysis using all 22 cytokines measured (panel C) and the more limited profile
(panel D) are also presented. The dendrogram at the bottom of panels C & D shows the clustering of febrile patients with (red lines) and without
(blues lines) bacterial infection, according to the cytokine profile selected (dendrodram at the left). The color map at the center indicates the cytokine
levels for each patient (brightest green is lowest level and brightest red is highest level measured). Altogether, these analyses show that febrile
patients with bacterial infection cannot be distinguished from those without.
doi:10.1371/journal.pone.0028870.g004
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Cytokine concentration values* P-values
Cytokines With bacterial infection (n=75) Without bacterial infection (n=51) Univariate
{ Multivariate
1
TNF-a 18.8 (13.2–109.6) 19.0 (11.8–56.3) 0.45 -
IL-1b 0 (0–244.3) 0 (0–220.0) 0.60 -
IL-1RA 675.3 (236.8–50,700) 619.8 (201.1–22,332) 0.36 -
IL-2 0 (0–108.5) 0 (0–90.2) 0.64 -
sIL-2R 828.5 (545.6–3,069) 844.9 (496.8–4,703) 0.41 -
IL-4 144.1 (96.0–174.3) 145.5 (78.9–213.3) 0.46 -
IL-5 0 (0–74.1) 0 (0–255.4) 0.78 -
IL-6 85.0 (0–11,490) 34.1 (0–2,222) 0.01 0.51
IL-8 49.5 (0–4,850) 25.2 (0–966.9) 0.02 0.34
IL-10 0 (0–238.9) 0 (0–302.4) 0.29 -
IL-12 851.6 (582.4–1,431) 848.8 (378.6–1,190) 0.78 -
IL-13 0 (0–96.4) 0 (0–356.7) 0.73 -
IL-15 26.6 (0–267.6) 27.0 (0–468.3) 0.61 -
IL-17 120.8 (93.3–145.3) 124.8 (95.5–177.5) 0.03 0.04
IFN-a 43.7 (33.3–131.7) 43.7 (29.0–699.5) 0.64 -
IFN-c 73.6 (48.6–132.9) 74.4 (49.4–93.6) 0.71 -
MCP-1 447.4 (113.6–22,000) 376.7 (97.4–7,613) 0.33 -
MIG 57.2 (37.6–6,900) 60.8 (19.0–1,652) 0.89 -
MIP-1a 56.2 (47.1–1,749) 55.9 (44.7–680.5) 0.92 -
MIP-1b 82.7 (47.2–3,531) 74.8 (33.0–855.0) 0.67 -
Eotaxin 61.7 (27.6–422.2) 52.9 (16.8–222.6) 0.23 -
GM-CSF 0 (0–569.9) 0 (0–333.7) 0.19 0.79
*Expressed in median (min-max); unit is pg/ml. Samples with non-detectable cytokine levels were considered to be zero pg/ml.
{Assessed using the Mann-Whitney test.
1Assessed using multiple logistic regression (all p-values,0.20 in univariate analyses were entered in the multivariate model).
doi:10.1371/journal.pone.0028870.t006
Figure 5. Principal component analysis and clustering of cytokine profiles in patients with (n=75) and without (n=51) bacterial
infection. Patients with (red dots) and without (blue dots) bacterial infection are represented according to the first three components computed using
principal component analysis of either all 22 cytokines (panel A), or a more limited profile using only IL-6, IL-8, IL-17 and GM-CSF (panel B). Hierarchical
cluster analysis using all 22 cytokines measured (panel C) and the more limited profile (panel D) are also presented. The dendrogram at the bottom of
panels C & D shows the clustering of patients with (red lines) and without (blues lines) bacterial infection, according to the cytokine profile selected
(dendrodram at the left). The color map at the center indicates the cytokine levels for each patient (brightest green is lowest level and brightest red is
highest level measured). Altogether, these analyses show that patients with bacterial infection cannot be distinguished from those without.
doi:10.1371/journal.pone.0028870.g005
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Nevertheless, the number of patients included is higher than in most
previous studies and this study had sufficient power to perform
robust multivariate analyses, as at least 10 patients were included for
each variable in these analyses. Furthermore, the number of patients
within each control group was significant as 71 patients without
severe sepsis, 116 patients without septic shock and 51 patients
without bacterial infection were included in the analyses. Although
our analysis focused on 22 cytokines, other molecules are known to
be involved, or, based on results from future studies, might be
implicated in the pathogenesis of sepsis [27,28]. We thus believe that
itmightbeimportanttorepeatthisoriginalanalyticapproachasnew
markers of sepsis become available. Finally, we have identified sIL-
2R, IL-1b, and IL-8, but not IL-6 or TNF-a, as independent
predictors of septic shock [29–31], while these latter two cytokines
were raised in most patients. This further underlines that IL-6 &
TNF-a are involved in the pathogenesis of sepsis but that they
cannot be considered independent markers, based on our analyses.
Conclusion
Altogether, our results suggest that previous studies aiming at
identifying serum cytokines that could be relevant in sepsis could
have used an inappropriate methodology. Indeed, as in previous
studies, we observed that individual cytokine biomarkers appeared
individually associated with severe sepsis and septic shock, but also
that none of these associations remained significant upon
Bonferroni’s correction. Therefore, these associations should be
considered exploratory until confirmed in larger prospective
studies. While we have identified individual cytokines that were
independently associated with severe sepsis and septic shock, or
both, we have shown that unambiguous cytokine profiles
corresponding to well-defined clinical groups cannot be identified
in this large cohort of patients with clinical signs of acute
inflammation. Therefore, our results indicate that multiplex
cytokine profiling may yet be of limited interest for the pragmatic
staging of septic patients in routine ED setting. Additional and
larger trials are now required to validate this finding. It is,
however, interesting to note that the cytokine profiles reported
here are highly heterogeneous, thus suggesting that groups of
patients who would be homogenous, not only clinically but also in
terms of pathogens, might indeed share identical profiles.
Therefore, a valuable addition for this analytic strategy could be
the assessment of patients presenting highly redundant clinical
patterns due to infections with well-defined pathogens [32].
Key messages
N Previous studies aiming at identifying serum cytokines in sepsis
have likely used an inappropriate methodology.
Table 7. Comparison of serum concentrations of cytokines between patients with proven bacterial infection and without bacterial
infection.
Cytokine concentration values* P-values
Cytokines
With proven bacterial infection
(n=31) Without bacterial infection (n=51) Univariate
{ Multivariate
1
TNF-a 18.3 (13.2–29.4) 19.0 (11.8–56.3) 0.051 0.80
IL-1b 0 (0–86.2) 0 (0–220.0) 0.21 -
IL-1RA 1058.0 (263.7–7,065) 619.8 (201.1–22,332) 0.22 -
IL-2 0 (0–42.4) 0 (0–90.2) 0.18 0.47
sIL-2R 823.0 (577.0–3,069) 844.9 (496.8–4,703) 0.28 -
IL-4 144.1 (96.0–174.3) 145.5 (78.9–213.3) 0.73 -
IL-5 0 (0–74.1) 0 (0–255.4) 0.73 -
IL-6 96.1 (0–1,731) 34.1 (0–2,222) 0.03 0.74
IL-8 53.3 (0–3599) 25.2 (0–966.9) 0.02 0.38
IL-10 0 (0–138.7) 0 (0–302.4) 0.35 -
IL-12 826.6 (582.4–996.8) 848.8 (378.6–1189.7) 0.21 -
IL-13 0 (0–96.4) 0 (0–356.7) 0.28 -
IL-15 26.1 (0–267.6) 27.0 (0–468.3) 0.75 -
IL-17 119.8 (93.3–136.7) 124.8 (95.5–177.5) 0.02 0.23
IFN-a 45.0 (33.3–72.2) 43.7 (29.0–699.5) 0.36 -
IFN-c 72.0 (48.6–92.8) 74.4 (49.4–93.6) 0.24 -
MCP-1 461.6 (189.6–3,647) 376.7 (97.4–7,613) 0.18 0.47
MIG 52.9 (37.6–2,951) 60.8 (19.0–1,652) 0.45 -
MIP-1a 55.6 (47.1–120.0) 55.9 (44.7–680.5) 0.88 -
MIP-1b 101.6 (51.7–516.9) 74.8 (33.0–855.0) 0.26 -
Eotaxin 59.4 (27.6–133.8) 52.9 (16.8–222.6) 0.97 -
GM-CSF 0 (0–569.9) 0 (0–333.7) 0.26 -
*Expressed in median (min-max); unit is pg/ml. Samples with non-detectable cytokine levels were considered to be zero pg/ml.
{Assessed using the Mann-Whitney test.
1Assessed using multiple logistic regression (all p-values,0.20 in univariate analyses were entered in the multivariate model).
doi:10.1371/journal.pone.0028870.t007
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sepsis and septic shock.
N Cytokine profiles corresponding to SIRS, severe sepsis and
septic shock cannot be identified in this large cohort of
patients.
N Multiplex cytokine profiling may yet be of limited interest for
the pragmatic staging of septic patients in routine ED setting.
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